ClinicalTrials.gg

Epstein-Barr Virus Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 175 studies for Epstein-Barr Virus Infections across more than 10 countries. 60 are recruiting or about to start. 62 of them are mainly about Epstein-Barr Virus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Burkitt Lymphoma: 1,154 studies, 218 open.

Status

Completed
66
Recruiting
43
Terminated
17
Status unknown
17
Not yet recruiting
13
Active, not recruiting
8

Phase

Phase 1
61
Phase 2
60
Phase 3
13
Early Phase 1
4
Phase 4
4

Where

United States
76
China
36
France
14
Canada
11
Australia
10
Taiwan
10

Who develops what

Add Epstein-Barr Virus Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bavarian Nordic, Eli Lilly and LucasBio here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
IrinotecanRecent, limited
Evidence
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)11 study
DocetaxelRecent, limited
Evidence
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 4 Jun 2027 est.LB-DTK-MV · LucasBio · Phase 2 main aimNCT07670468 Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation. — primary endpoint: CMV viral load · 27 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Epstein-Barr Virus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 1 open · Immune checkpoint inhibitors 1 open

Coming up

21studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger. 23 (53%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (14%) take healthy volunteers.

Recruiting studies that take each age, of 43
AgeWomenMen
1019 (44%)19 (44%)
1840 (93%)40 (93%)
3037 (86%)37 (86%)
4036 (84%)36 (84%)
5036 (84%)36 (84%)
6535 (81%)35 (81%)
7530 (70%)30 (70%)
8525 (58%)25 (58%)

Across all 175 studies, recruiting or not: 35% stop at 75 or younger and 22% at 65; 49% take children; 0% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 175. Browse all 175 → or search them.